Palbociclib (Ibrance) Coverage and Prior Authorization
Customize your policy alerts
Sign up for QualChoice Policy AR.QC.HIM.PA.173 alerts
Get alerted when Policy AR.QC.HIM.PA.173 changes without checking for updates manually.
Monitor payer policy activity
QualChoice Commercial coverage and prior authorization for palbociclib (Ibrance) and generic palbociclib in adults with specified breast cancers, soft tissue sarcoma, uterine neoplasms, and other requested indications.
The policy was adapted from HIM.PA.173 and maintains redirection to Kisqali and Verzenio for breast cancer.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.